Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7453255 | 0.83 | STAT3 (0.47) | FFAR1ACHESTAT3CYP2C19POLB | |
| SCHEMBL10908214 | 0.83 | FFAR1 (0.54) | FFAR1ACHESTAT3CYP26A1CYP2C19 | |
| SCHEMBL5864212 | 0.81 | TAAR1 (0.54) | CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL4483465 | 0.81 | TAAR1 (0.54) | CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL4483463 | 0.81 | TAAR1 (0.54) | CYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL2223571 | 0.81 | FNTA (0.54) | FFAR1ACHESTAT3CYP26A1CYP2C19 | |
| SCHEMBL186610 | 0.80 | GABBR2 (0.55) | CYP2C19SMN1; SMN2 | |
| SCHEMBL904490 | 0.80 | GABBR2 (0.55) | CYP2C19SMN1; SMN2 | |
| SCHEMBL904476 | 0.80 | GABBR2 (0.55) | CYP2C19SMN1; SMN2 | |
| SCHEMBL11760750 | 0.80 | ALDH1A1 (0.48) | FFAR1CYP2C19KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-4002660-A | ANTIBACTERIAL AGENTS | MORTON-NORWICH PRODUCTS, INC. (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | FFAR1 339/4885ACHE 3735/4885STAT3 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.